research use only

AZD1480 JAK inhibitor

Name: AZD1480
Brand: Selleck Chemicals
SKU: S2162
Availability: InStock
Rating: 5 (123 reviews)

Cat.No.S2162

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.

Chemical Structure

Molecular Weight: 348.77

Jump to

Quality Control

Batch: Purity: 99.16%

99.16

Related Targets	EGFR STAT Pim
Other JAK Inhibitors	WP1066 Momelotinib (CYT387) Filgotinib (GLPG0634) AT9283 Gandotinib (LY2784544) TG101209 Cerdulatinib (PRT062070) hydrochloride Pacritinib NVP-BSK805 2HCl WHI-P154

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SW620	Function Assay	5 μM	48 h	DMSO	blocks JAK2/STAT3 signaling	25954974
LoVo	Function Assay	5 μM	48 h	DMSO	blocks JAK2/STAT3 signaling	25954974
HN5	Growth Inhibition Assay		72 h		EC50=3.81 ± 1.99 μM	25810010
Cal33	Growth Inhibition Assay		72 h		EC50=3.37 ± 0.75 μM	25810010
UM-22B	Growth Inhibition Assay		72 h		EC50=2.66 ± 0.24 μM	25810010
686LN	Growth Inhibition Assay		72 h		EC50=2.05 ± 1.33 μM	25810010
UM SCC-1	Growth Inhibition Assay		72 h		EC50=1.67 ± 0.42 μM	25810010
UM-22A	Growth Inhibition Assay		72 h		EC50=1.32 ± 0.39 μM	25810010
OSC19	Growth Inhibition Assay		72 h		EC50=1.26 ± 0.20 μM	25810010
PCI-52	Growth Inhibition Assay		72 h		EC50=1.00 ± 0.09 μM	25810010
PCI-15B	Growth Inhibition Assay		72 h		EC50=0.99 ± 1.74 μM	25810010
UMSCC-1	Function Assay	0.0005-1.6 μM	24 h		abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
Cal33	Function Assay	0.0005-3.8 μM	24 h		abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
HH5	Function Assay	0.0005-3.8 μM	24 h		abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
UM-22A	Function Assay	0.0005-1.6 μM	24 h		abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
A1847	Function Assay	0.05-10 μM	24 h	DMSO	reduces phosphorylated STAT3 levels	25646015
OVCAR-5	Function Assay	0.05-10 μM	24 h	DMSO	reduces phosphorylated STAT3 levels	25646015
OVCAR-8	Function Assay	0.05-10 μM	24 h	DMSO	reduces phosphorylated STAT3 levels	25646015
MOVCAR-5447	Function Assay	0.05-10 μM	24 h	DMSO	reduces phosphorylated STAT3 levels	25646015
MOVCAR-5009	Function Assay	0.05-10 μM	24 h	DMSO	reduces phosphorylated STAT3 levels	25646015
A1847	Cell Viability Assay	0.05-10 μM	72 h	DMSO	reduces cell viability at the concerntration of 5 μM	25646015
OVCAR-5	Cell Viability Assay	0.05-10 μM	72 h	DMSO	reduces cell viability at the concerntration of 5 μM	25646015
OVCAR-8	Cell Viability Assay	0.05-10 μM	72 h	DMSO	reduces cell viability at the concerntration of 5 μM	25646015
OVCAR-5	Apoptosis Assay	0.5/1/5 μM	48 h	DMSO	induces significant apoptosis at high concerntration	25646015
OVCAR-8	Apoptosis Assay	0.5/1/5 μM	48 h	DMSO	induces significant apoptosis at high concerntration	25646015
AKRSL	Cell Viability Assay		72 h		IC50＞10 μM	25504635
PALJDL	Cell Viability Assay		72 h		IC50=2.4 μM	25504635
MO4	Function Assay	0.5/1/5 μM	6 h		inhibits P-STAT3 expression	25149535
DU145	Function Assay	0-200 nM	1 h		suppresses IL-6-activated Stat3 and ERK1/2 signaling	24577942
DU145	Function Assay	800 nM	72 h		suppresses IL-6-induced migratory	24577942
CWR22Rv1	Function Assay	800 nM	72 h		suppresses IL-6-induced migratory	24577942
N592	Growth Inhibition Assay				IC50=0.84 μM	24158701
H82	Growth Inhibition Assay				IC50=1.37 μM	24158701
GLC4	Growth Inhibition Assay				IC50=1.79 μM	24158701
H526	Growth Inhibition Assay				IC50=3.08 μM	24158701
H1173	Growth Inhibition Assay				IC50=2.39 μM	24158701
DMS114	Growth Inhibition Assay				IC50=0.73 μM	24158701
NCI-N592	Function Assay	0.3/1/3 μM	24 h		induces G2/M cell cycle arrest	24158701
GLC4	Function Assay	0.3/1/3 μM	24 h		induces G2/M cell cycle arrest	24158701
NCI-H82	Function Assay	0.3/1/3 μM	24 h		induces G2/M cell cycle arrest	24158701
NCI-N592	Apoptosis Assay	0.3/1/3 μM	48 h		increases the level of cleaved-Caspase 3	24158701
GLC4	Apoptosis Assay	0.3/1/3 μM	48 h		increases the level of cleaved-Caspase 3	24158701
NCI-H82	Apoptosis Assay	0.3/1/3 μM	48 h		increases the level of cleaved-Caspase 3	24158701
CWR22Rv1	Apoptosis Assay				IC50=0.482 μM	23942095
CWR22Pc	Apoptosis Assay				IC50=0.438 μM	23942095
PC-3	Apoptosis Assay				IC50=1.755 μM	23942095
DU145	Apoptosis Assay				IC50=3.517 μM	23942095
RC165N	Apoptosis Assay				IC50=2.083 μM	23942095
ARPE19	Growth Inhibition Assay			DMSO	IC50=24.38 μM	23531921
HEK293	Growth Inhibition Assay			DMSO	IC50=8.67 μM	23531921
KCNR	Growth Inhibition Assay			DMSO	IC50=0.46 μM	23531921
SY5Y	Growth Inhibition Assay			DMSO	IC50=0.36 μM	23531921
BE2	Growth Inhibition Assay			DMSO	IC50=0.71 μM	23531921
AS	Growth Inhibition Assay			DMSO	IC50=1.53 μM	23531921
NGP	Growth Inhibition Assay			DMSO	IC50=0.56 μM	23531921
IMR32	Growth Inhibition Assay			DMSO	IC50=0.66 μM	23531921
LAN5	Growth Inhibition Assay			DMSO	IC50=1.04 μM	23531921
RH18	Growth Inhibition Assay			DMSO	IC50=1.42 μM	23531921
RH30	Growth Inhibition Assay			DMSO	IC50=1.25 μM	23531921
RH17	Growth Inhibition Assay			DMSO	IC50=2.51 μM	23531921
RH28	Growth Inhibition Assay			DMSO	IC50=4.28 μM	23531921
RH36	Growth Inhibition Assay			DMSO	IC50=5.37 μM	23531921
RH41	Growth Inhibition Assay			DMSO	IC50=0.48 μM	23531921
RD	Growth Inhibition Assay			DMSO	IC50=4.32 μM	23531921
TC32	Growth Inhibition Assay			DMSO	IC50=3.85 μM	23531921
TC71	Growth Inhibition Assay			DMSO	IC50=4.33 μM	23531921
KCNR	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	DMSO	induces an increase in caspase 3/7 activity	23531921
SY5Y	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	DMSO	induces an increase in caspase 3/7 activity	23531921
Rh18	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	DMSO	induces an increase in caspase 3/7 activity	23531921
TC32	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	DMSO	induces an increase in caspase 3/7 activity	23531921
KCNR	Function Assay	0.5/1.0/2.5/5 μM	24 h	DMSO	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
SY5Y	Function Assay	0.5/1.0/2.5/5 μM	24 h	DMSO	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
Rh18	Function Assay	0.5/1.0/2.5/5 μM	24 h	DMSO	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
TC32	Function Assay	0.5/1.0/2.5/5 μM	24 h	DMSO	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
TPC-1	Growth Inhibition Assay	1 µM	0-4 d	DMSO	inhibits cell growth after 2 d treatment	23056499
MZ-CRC1	Growth Inhibition Assay	1 µM	0-5 d	DMSO	inhibits cell growth after 1 d treatment	23056499
TT	Growth Inhibition Assay	1 µM	0-4 d	DMSO	inhibits cell growth after 1 d treatment	23056499
TPC-1	Function Assay	1 µM	72 h	DMSO	induces G1 blockage	23056499
MZ-CRC1	Function Assay	1 µM	72 h	DMSO	induces G1 blockage	23056499
TT	Function Assay	1 µM	72 h	DMSO	induces G1 blockage	23056499
MZ-CRC1	Apoptosis Assay	1 µM	48 h	DMSO	induces apoptosis	23056499
TT	Apoptosis Assay	1 µM	48 h	DMSO	induces apoptosis	23056499
HD-LM2	Growth Inhibition Assay		72 h	DMSO	IC50=7.844 μM	22829094
L-428	Growth Inhibition Assay		72 h	DMSO	IC50=7.947 μM	22829094
KM-H2	Growth Inhibition Assay		72 h	DMSO	IC50=1.308 μM	22829094
L-540	Growth Inhibition Assay		72 h	DMSO	IC50=8.216 μM	22829094
HD-LM2	Function Assay	0.1/0.5/1/5 μM	72 h	DMSO	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
L-428	Function Assay	0.1/0.5/1/5 μM	72 h	DMSO	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
KM-H2	Function Assay	0.1/0.5/1/5 μM	72 h	DMSO	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
L-540	Function Assay	0.1/0.5/1/5 μM	72 h	DMSO	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
HD-LM2	Apoptosis Assay	1/5 μM	72 h	DMSO	induces apoptosis	22829094
L-428	Apoptosis Assay	1/5 μM	72 h	DMSO	induces apoptosis	22829094
KM-H2	Apoptosis Assay	1/5 μM	72 h	DMSO	induces apoptosis	22829094
L-540	Apoptosis Assay	1/5 μM	72 h	DMSO	induces apoptosis	22829094
U251-MG	Function Assay	1 µM	0-16 h		inhibits constitutive STAT-3 and JAK2 activation	22027691
U87-MG	Function Assay	1 µM	0-16 h		inhibits constitutive STAT-3 and JAK2 activation	22027691
4C8	Function Assay	1 µM	0-16 h		inhibits constitutive STAT-3 and JAK2 activation	22027691
U251-MG	Growth Inhibition Assay	1/10 µM	24/48/72 h		inhibits cell proliferation at a concentration of 10 µM	22027691
U87-MG	Growth Inhibition Assay	1/10 µM	24/48/72 h		inhibits cell proliferation at a concentration of 10 µM	22027691
4C8	Growth Inhibition Assay	1/10 µM	24/48/72 h		inhibits cell proliferation at a concentration of 10 µM	22027691
U266	Apoptosis Assay	0.5-2 μM	48/72 h		induces apoptosis dose dependently	21164517
Kms.11	Apoptosis Assay	0.5-2 μM	48/72 h		induces apoptosis dose dependently	21164517
8226	Apoptosis Assay	0.5-2 μM	48/72 h		induces apoptosis dose dependently	21164517
SET2	Growth inhibition assay		48 hrs		Growth inhibition of human SET2 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.016 μM.	21138246
SET2	Function assay		1 hr		Inhibition of Stat3 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.023 μM.	21138246
SET2	Function assay		1 hr		Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.025 μM.	21138246
HEL	Function assay		1 hr		Inhibition of Stat5 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.041 μM.	21138246
Ba/F3	Function assay				Inhibition of Stat5 phosphorylation in mouse Ba/F3 cells expressing TEL-Jak2, IC50 = 0.046 μM.	21138246
UKE1	Growth inhibition assay		48 hrs		Growth inhibition of human UKE1 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.054 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs		Growth inhibition of mouse BA/F3 cells expressing Tel-JAK2 kinase after 48 hrs by MTS assay, GI50 = 0.06 μM.	21138246
HEL	Function assay		1 hr		Inhibition of Stat3 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.08 μM.	21138246
HEL	Growth inhibition assay		48 hrs		Growth inhibition of human HEL cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.39 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs		Growth inhibition of mouse BA/F3 cells expressing Tel-JAK1 kinase after 48 hrs by MTS assay, GI50 = 0.7 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs		Growth inhibition of mouse BA/F3 cells expressing Tel-Tyk2 kinase after 48 hrs by MTS assay, GI50 = 2 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs		Growth inhibition of mouse BA/F3 cells expressing Tel-JAK3 kinase after 48 hrs by MTS assay, GI50 = 2.1 μM.	21138246
UKE1	Function assay		1 hr		Inhibition of Stat5 phosphorylation in human UKE1 cells after 1 hr by Western blotting	21138246
SW620	Cell cycle assay	3.3 uM	24 hrs		Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 3.3 uM after 24 hrs by flow cytometry	21138246
HEL	Function assay	0.3 uM	5 mins		Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting	21138246
HEL	Function assay	0.3 uM	30 to 60 mins		Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting	21138246
BA/F3	Antitumor assay	30 mg/kg	12 hrs		Antitumor activity against mouse BA/F3 cells expressing Tel-JAK2 xenografted in NCr mouse assessed as reduction of phosphorylated Stat5 level in spleen at 30 mg/kg, po after 12 hrs by Western blotting	21138246
HEL	Function assay	0.3 uM	5 mins		Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting	21138246
HEL	Function assay	0.3 uM	30 to 60 mins		Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting	21138246
Hs578T	Function assay	1 uM	24 hrs		Inhibition of STAT3C-mediated transcription in human Hs578T cells at 1 uM after 24 hrs by luciferase reporter gene assay	24978112
NCI-H1975	Function assay	0.003 to 3 uM	2 hrs		Inhibition of JAK1 in human NCI-H1975 cells assessed as reduction in STAT3 phosphorylation at 0.003 to 3 uM after 2 hrs by Western blot analysis	26614408
HEL 92.1.7	Function assay		2 hrs		Inhibition of JAK2 in human HEL 92.1.7 cells assessed as reduction in STAT5 phosphorylation after 2 hrs by Western blot analysis	26614408
DAOY	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
SK-N-SH	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
BT-12	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
Rh41	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (200.7 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (14.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (14.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	348.77	Formula	C₁₄H₁₄ClFN₈	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	935666-88-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F

Mechanism of Action

Targets/IC₅₀/Ki	JAK2 (Cell-free assay) 0.26 nM
In vitro	5μM AZD1480 induces G2/M arrest and cell death by inhibiting Aurora kinases. This compound is a potent JAK2 inhibitor that can suppress growth, survival, as well as FGFR3 and STAT3 signaling and downstream targets including Cyclin D2 in human multiple myeloma cells. At low micromolar concentrations, it blocks cell proliferation and induces apoptosis of myeloma cell lines. This chemical effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis. It is a potent, competitive small-molecule inhibitor of JAK1/2 kinase, and that it is capable of inhibiting STAT3 phosphorylation and tumor growth in a STAT3-dependent manner. This inhibitor inhibits tumor angiogenesis and metastasis in part by affecting the tumor microenvironment.
Kinase Assay	kinase assays
Kinase Assay	Inhibition studies of AZD1480 are performed using recombinant Jak1, Jak2, or Jak3 under buffer conditions of 50 mM HEPES pH 7.3, 1 mM DTT, 0.01% Tween-20, 50 mM/ml BSA, and 10 mM MgCl₂. Jak3 enzyme is expressed as N-terminal GST fusion in insect cells and purified by glutathione-affinity and size-exclusion chromatographies. Enzymes are assayed in the presence of this compound (10 point dose response, in triplicate, from 8.3 μM to 0.3 nM in half-log dilution steps) using 1.5 μM peptide substrate (Jak1: FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2 and Jak3: FAM-SRCtide) and screened under their respective ATP Km (Jak1: 55 μM, Jak2: 15 μM, Jak3: 3 μM) and approximated physiological ATP concentration of 5 mM. Phosphorylated and unphosphorylated peptides are separated and quantified by a Caliper LC3000 system for calculating percent inhibition.
In vivo	AZD1480 inhibits the STAT3 phosphorylation in an xenograft model of human solid tumors and multiple myeloma. In vivo, this compound inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial glioblastoma (GBM) tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by this chemical should be considered for study in the treatment of patients with GBM tumors. It blocks lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, this agent reduces angiogenesis and metastasis in a human xenograft tumor model. The Jak2 inhibitor suppresses the growth of human solid tumor xenografts harboring persistent Stat3 activity.
References	[1] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255510/ [2] https://pubmed.ncbi.nlm.nih.gov/21164517/ [3] https://pubmed.ncbi.nlm.nih.gov/22027691/ [4] https://pubmed.ncbi.nlm.nih.gov/21920898/ [5] https://pubmed.ncbi.nlm.nih.gov/19962667/

Applications

Methods	Biomarkers	PMID
Western blot	p-STAT3 / STAT3 / p-JAK2 / JAK2 p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2	22027691
Immunofluorescence	pSTAT5	30140255
Growth inhibition assay	Cell proliferation Cell viability	22027691

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01219543	Terminated	Solid Tumour\|Advanced Solid Malignancies\|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma\|EGFR and/or ROS Mutant NSCLC\|Lung Metastasis Carcinoma\|Gastric Cancer	AstraZeneca	November 2010	Phase 1
NCT01112397	Terminated	Solid Malignancies	AstraZeneca	April 2010	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):